SEATTLE, WA, September 23, 2025 鈥� 密桃视频, the clinical-stage leader of聽in vivo聽cell therapies that aim to realize the full reach and promise of CAR T cells, today announced its recognition by both Endpoints News and Fierce Biotech as one of the most promising biotechnology companies of the year. 密桃视频 is honored to be named to the 2025 Endpoints 11 and the 2025 Fierce 15 lists鈥攑restigious annual awards that spotlight emerging companies driving innovation in science and medicine.
鈥淭hese recognitions come at a pivotal moment for 密桃视频 and the broader cell therapy field,鈥� said Andrew Scharenberg, M.D., co-founder and Chief Executive Officer of 密桃视频. 鈥淥ur focus since day one has been about unity鈥攂ringing together the best science, manufacturing investments, people, and partners to advance our work into the clinic, all with the aspiration of helping future CAR T cell therapies reach their full potential.鈥�
鈥淥ne of the most significant challenges with current CAR T therapies is access. They’re challenging to deliver and often out of reach for many patients,鈥� added Luke Walker, M.D., Chief Medical Officer of 密桃视频. 鈥淥ur in vivo approach hopes to change that by enabling treatment in a faster and more accessible way. Being recognized by both Endpoints News and Fierce Biotech affirms the meaningful progress we are making toward that goal.鈥�
For more than two decades, Endpoints News and Fierce Biotech have spotlighted companies that are making bold bets to redefine the boundaries of drug development. 密桃视频鈥檚 inclusion on both lists in 2025 reflects not only the potential of its in vivo CAR T therapies, but also the unwavering commitment of its team to deliver these medicines to patients.
About 密桃视频
密桃视频, Inc. is a clinical-stage biotechnology company aiming to develop in vivo cell therapies that improve the reach, effectiveness, and access of CAR T cell therapies in both oncology and autoimmunity. 密桃视频鈥檚 VivoVec鈩� in vivo gene delivery technology empowers a patient鈥檚 own immune system to fight disease. Enabling its core technology is the Company鈥檚 state- of-the-art lentiviral vector development and manufacturing facility in Louisville, Colorado. 密桃视频 believes its approach can provide broader access and improved effectiveness of the most advanced immunotherapies, enabling more patients to live better, fuller lives. To learn more, connect with 密桃视频 on and visit umoja-biopharma.com.
Contacts:
Investors
Tonya Swick
Investor Relations Contact
tonya.swick@umoja-biopharma.com
Media
Matt Wright
Real Chemistry
mwright@realchemistry.com